Clinical Trials Logo

Clinical Trial Summary

In this study, the investigators will measure affective, neurocognitive and behavioral outcomes related to chronic use of opioids and benzodiazepines (screening phase), and in response to the administration of the opioid morphine, the benzodiazepine alprazolam, morphine then alprazolam, alprazolam then morphine, morphine+alprazolam simultaneously, and placebo (laboratory pharmacology experiment). The latter will enable the investigators to assess the effects of an opioid alone, benzodiazepine alone, concurrent and simultaneous administration of opioid+benzodiazepine, relative to a placebo control.


Clinical Trial Description

The investigators propose that benzodiazepine/opioid polysubstance abuse is perpetuated by a dual-deficit in affective/hedonic regulation (difficulties modulating emotional reactions relative to the context and the person's long-term goals). Furthermore, the investigators propose that this dual-deficit biases neurocognition (interferes with executive function) and behaviors (guided by negative reinforcement processes such that polysubstance use acutely blunts aversive states and directs actions away from natural rewards). The scientific premise for this project builds on George Koob's foundational concept that addiction is a 'reward-deficit/stress-surfeit disorder'. There is an urgent need to obtain clinical pharmacology and mechanistic data to test this hypothesis of dual-deficit in affective/hedonic regulation. This study will use human laboratory methods to test affective, neurocognitive and behavioral mechanisms that maintain benzodiazepine/opioid polysubstance abuse. The screening phase of this human laboratory study will include measures of affective dysregulation related to benzodiazepine/opioid polysubstance use behaviors. These include distress tolerance, pain sensitivity and nocebo responding, and biomarkers (e.g. plasma cortisol). Also, the investigators will include behavioral measures of drug and non-drug reinforcement (e.g. economic simulations of price elasticity of alprazolam and morphine) and neurocognition (e.g. drug attentional bias, response inhibition, cognitive flexibility). During the pharmacology study the investigators will administer oral placebo, morphine alone and alprazolam doses alone, as well as morphine and alprazolam sequentially (in counterbalanced order) and simultaneously. Following each drug administration, the investigators will measure responses in affective (e.g. anxiety levels, distress tolerance), neurocognitive (e.g. executive function, learning) and behavioral domains (e.g. impulsivity, psychomotor function, reinforcer preferences). The lab study is highly significant because we lack prospective, controlled, dose-response studies that identify whether opioids, benzodiazepines, and their combination modulate core phenotypes that underlie this harmful polysubstance abuse. Testing effects of both sequential and simultaneous benzodiazepine/opioid administration within the same individuals will establish a firm foundation for understanding which phenotypes are sensitive to disruption and may respond to treatment. Findings from this study will help to focus clinical assessment and identify mechanisms that maintain benzodiazepine/opioid polysubstance abuse, toward the development of novel medication-assisted, evidence-based psychosocial interventions. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05006079
Study type Interventional
Source Wayne State University
Contact Mark K Greenwald, PhD
Phone 313-993-3965
Email mgreen@med.wayne.edu
Status Recruiting
Phase Phase 2
Start date March 13, 2024
Completion date December 2025

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04839978 - Community Trial in the Cherokee Nation N/A
Completed NCT05593341 - Opioid Education in Total Knee Arthroplasty N/A
Terminated NCT04495374 - Oral Pregabalin as Preemptive Analgesia in Abdominal Hysterectomy Phase 4
Terminated NCT03822962 - Pain Management Following Sinus Surgery Early Phase 1
Completed NCT03936985 - Validation of a Community Pharmacy-Based Prescription Drug Monitoring Program Risk Screening Tool
Active, not recruiting NCT01740414 - Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers Phase 2
Completed NCT00499746 - The Discriminative Effects of Tramadol in Humans Phase 1/Phase 2
Completed NCT03684681 - The Navigator Trial N/A
Completed NCT04340622 - Efficacy And Safety Of An Innovative Treatment Of Opiate Use Disorders N/A
Completed NCT04018664 - Oral Abuse Potential Study of Nalbuphine Phase 1
Completed NCT00699010 - Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse Phase 2
Completed NCT04710069 - Postoperative Opt-In Narcotic Treatment Study N/A
Terminated NCT03992079 - A Multimodal Enhanced Recovery Program in Anorectal Surgery N/A
Active, not recruiting NCT03570099 - Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications
Completed NCT02804152 - Program for Pain & Prescription Opioid Use in Pregnancy N/A
Active, not recruiting NCT01632982 - Mobile Psychosocial Interventions for MMT Clients N/A
Active, not recruiting NCT01136356 - A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals Phase 1/Phase 2
Not yet recruiting NCT05706311 - Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool N/A
Completed NCT03743493 - PCORnet Opioid Surveillance Study
Completed NCT03143855 - Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder Phase 1